Merck KGAA Courts US, China Investors To Accelerate Immuno-Oncology Development
Executive Summary
EMD Serono Inc.'s Head of BioPharma External Innovation Ravi Kiron outlines to Brian Yang how the Merck KGAA Group is courting US and Chinese Investors to fund such projects with a size of $100-200m.
You may also be interested in...
Forty Seven's IO Antibody Attracts Two Big Pharma Partners
Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.